New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
10:11 EDTBYI, VCRA, PX, BPOP, IMMUHigh option volume stocks: VCRA IMMU PX BYI BPOP
News For VCRA;IMMU;PX;BYI;BPOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTPXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTPXPraxair downgraded to Neutral at RW Baird
As previously reported, Baird downgraded Praxair to Neutral form Outperform citing choppy trends in Brazil and China in addition to currency headwinds. Baird lowered its price target to $133 from $136 on Praxair shares.
06:30 EDTPXPraxair downgraded to Neutral from Outperform at RW Baird
January 22, 2015
09:31 EDTPXPraxair awarded NASA contract to supply hydrogen to space programs
Subscribe for More Information
08:14 EDTBPOPPopular reports Q4 EPS 50c, consensus 58c
Reports Q4 EPS for continuing operations of 41c and from discontinued operations of 9c. Reports Q4 adjusted net income of $80.8M. Reports Q4 adjusted net interest margin of 4.70% vs. 4.64% in Q3. Reports Common Equity Tier 1 ratio of 15.92% and tangible book value per share of $35.93 at December 31, 2014. Reports Q4 provision for loan losses on non-covered loans of $51.64M and a reversal of provision for loan losses on covered loans of $3.65M.
January 21, 2015
15:27 EDTBPOPNotable companies reporting before tomorrow's open
Subscribe for More Information
January 20, 2015
09:33 EDTPXPraxair sent warning letter from FDA
The FDA warning letter, dated Jan. 7, cites an inspection that revealed quality system violations. Reference Link
08:46 EDTIMMUImmunomedics reports Phase 1/2 results with sacituzumab govitecan
Immunomedics announced that sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, or ADC, produces partial response, or PR, in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated. Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression, or TTP, exceeding that of last prior therapy in many cases. Response and TTP were evaluated by computed tomography, or CT, based on RECIST criteria. Patented and developed by the company, sacituzumab govitecan was created by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to antibody to a humanized antibody that targets the TROP-2 receptor expressed by many solid cancers. SN-38 is the active metabolite of irinotecan, which is used to treat certain solid cancers, particularly metastatic colorectal cancers, as a part of combination therapies, so its pharmacology and properties are well-known. Despite the late-stage setting, 1 patient in each of the colorectal and esophageal cancer groups had a partial response after receiving more than 2 doses of the ADC. For all 4 cancer types, the disease stabilization rate exceeded 50%.
January 16, 2015
13:34 EDTBPOPManning & Napier Advisors reports 5.76% passive stake in Popular
Subscribe for More Information
10:06 EDTPXHigh option volume stocks
Subscribe for More Information
09:20 EDTPXPraxair ses currency devaluation cutting FY15 EPS by 7c, revenue by $100M
09:19 EDTPXPraxair sees charge of about $131M in Q4
Subscribe for More Information
09:19 EDTPXPraxair to report Venezuela results at SICAD II exchange rates
Praxair announced that it will no longer use the Venezuelan government’s official exchange rate of 6.3 bolivars per U.S. dollar to translate the financial statements of its Venezuelan business. Effective December 31, 2014, the company has adopted the Venezuelan government’s SICAD II currency exchange system rate of approximately 50 bolivars per U.S. dollar. As a result of the change, Praxair expects to record in Q4 results a charge of about $131M or 45c per diluted share. This charge includes remeasurement of monetary assets and liabilities to the SICAD II rate and related fixed asset impairments and inventory adjustments. Praxair estimates that the currency devaluation to the SICAD II rate will reduce the company’s full-year 2015 revenues by approximately $100M and diluted EPS by about 7c compared to 2014.
January 15, 2015
10:07 EDTPXHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use